Identification Lysosome-associated protein transmembrane-4 as a novel therapeutic target for osteosarcoma treatment
Identification Lysosome-associated protein transmembrane-4 as a novel therapeutic target for osteosarcoma treatment
复制标题
鉴定溶酶体相关蛋白跨膜-4作为骨肉瘤治疗的新靶点
作者：
Zhe-Xiang Wang;Meng-Yang Guo;Jing Ren;Gui-Shi Li;Xu-Guo Sun
目的：本研究旨在检测我院骨肉瘤组织标本中溶酶体相关蛋白跨膜蛋白4（LAPTM4B）的表达情况，探讨LAPTM4B表达与骨肉瘤患者临床病理特征的相关性。研究方法：采用免疫组化（IHC）法检测62例骨肉瘤组织及相应非肿瘤组织中LAPTM4B的表达水平。根据LAPTM4B在骨肉瘤组织中的表达强度，将骨肉瘤患者分为LAPTM4B高表达组和低表达组。此外，评估了LAPTM4B表达水平与临床病理学特征之间的潜在相关性。并通过集落形成实验和transwell实验检测LAPTM4B对人成骨肉瘤细胞增殖和侵袭能力的影响。我们通过体内动物模型进一步探讨了LAPTM4B对肿瘤生长和转移的潜在影响。结果：LAPTM 4B在人骨肉瘤组织中呈高表达。我们发现LAPTM 4B与骨肉瘤患者的临床特征包括肿瘤大小（p=0.004*）和临床分期（p=0.035*）之间的显著性，p值为。我们的研究结果进一步表明，LAPTM 4B的消融明显抑制骨肉瘤细胞在体外的增殖和侵袭，并抑制肿瘤的生长和转移。结论：我们研究了LAPTM4B在骨肉瘤进展中的潜在参与，因此证实LAPTM4B是骨肉瘤的新治疗靶点。
Objective: The aim of the study is to evaluate the expression of Lysosome-associated protein transmembrane-4 (LAPTM4B) in human osteosarcoma tissue samples collected in our hospital, and to explore the possible correlations between the clinical pathological features of osteosarcoma patients and LAPTM4B expression. Methods: Immunohistochemical (IHC) assays were performed to detect the expression levels of LAPTM4B in 62 tissue samples of osteosarcoma tissues and corresponding non-tumor tissues. According to LAPTM4B staining intensity in tumor tissues, osteosarcoma patients were classified into LAPTM4B high expression and low expression groups. In addition, the potential correlations between LAPTM4B expression levels and clinical pathological features were evaluated. Also, we detected the effects of LAPTM4B on the proliferation and invasion of esteosarcoma cells through colony formation assay and transwell assay, respectively. We further explored the potential effects of LAPTM4B on tumor growth and metastasis by in vivo animal model. Results: We revealed that LAPTM4B was high expression in human osteosarcoma tissues. We found the significance between LAPTM4B and clinical features including tumor size (p=0.004*) and clinical stage (p=0.035*) of osteosarcoma patients, with the p value. Our results further demonstrated that ablation of LAPTM4B obviously blocked the proliferation and invasion of osteosarcoma cells in vitro and restrained tumor growth and metastasis in mice..Conclusions: We investigated the potential involvement of LAPTM4B in osteosarcoma progression, and therefore confirmed LAPTM4B as a novel therapeutic target for osteosarcoma.